CDK2/4/6 inhibitor SYH2043

{
  "id": "MLC-T-ONC-012451",
  "term": "CDK2/4/6 inhibitor SYH2043",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable small molecule inhibitor of cyclin-dependent kinase (CDK) types 2 (CDK2), 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, CDK2/4/6 inhibitor SYH2043 selectively targets and inhibits CDK2, CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase and prevents CDK-mediated G1-S-phase transition. This leads to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDKs are serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation and are upregulated in many tumor cell types.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cdk2-4-6-inhibitor-syh2043/"
}